These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 25906756)

  • 1. Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis.
    Hobson-Webb LD; Hehir M; Crum B; Visser A; Sanders D; Burns TM
    Muscle Nerve; 2015 Aug; 52(2):211-5. PubMed ID: 25906756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil in the therapy of severe myasthenia gravis.
    Schneider C; Gold R; Reiners K; Toyka KV
    Eur Neurol; 2001; 46(2):79-82. PubMed ID: 11528156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study.
    Oskarsson B; Rocke DM; Dengel K; Richman DP
    Neurology; 2016 Mar; 86(12):1159-63. PubMed ID: 26850977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.
    Sanders DB; Hart IK; Mantegazza R; Shukla SS; Siddiqi ZA; De Baets MH; Melms A; Nicolle MW; Solomons N; Richman DP
    Neurology; 2008 Aug; 71(6):400-6. PubMed ID: 18434638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability.
    Meriggioli MN; Ciafaloni E; Al-Hayk KA; Rowin J; Tucker-Lipscomb B; Massey JM; Sanders DB
    Neurology; 2003 Nov; 61(10):1438-40. PubMed ID: 14638974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate mofetil treatment in dogs with serologically diagnosed acquired myasthenia gravis: 27 cases (1999-2008).
    Dewey CW; Cerda-Gonzalez S; Fletcher DJ; Harb-Hauser MF; Levine JM; Badgley BL; Olby NJ; Shelton GD
    J Am Vet Med Assoc; 2010 Mar; 236(6):664-8. PubMed ID: 20225980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients.
    Hehir MK; Burns TM; Alpers J; Conaway MR; Sawa M; Sanders DB
    Muscle Nerve; 2010 May; 41(5):593-8. PubMed ID: 20405499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases.
    Chaudhry V; Cornblath DR; Griffin JW; O'Brien R; Drachman DB
    Neurology; 2001 Jan; 56(1):94-6. PubMed ID: 11148242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study.
    Narayanaswami P; Sanders DB; Thomas L; Thibault D; Blevins J; Desai R; Krueger A; Bibeau K; Liu B; Guptill JT;
    Lancet Neurol; 2024 Mar; 23(3):267-276. PubMed ID: 38365379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of mycophenolate mofetil as a rescue agent in the treatment of severe generalized myasthenia gravis in three dogs.
    Abelson AL; Shelton GD; Whelan MF; Cornejo L; Shaw S; O'Toole TE
    J Vet Emerg Crit Care (San Antonio); 2009 Aug; 19(4):369-74. PubMed ID: 25164637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longterm followup after tapering mycophenolate mofetil during maintenance treatment for proliferative lupus nephritis.
    Laskari K; Tzioufas AG; Antoniou A; Moutsopoulos HM
    J Rheumatol; 2011 Jul; 38(7):1304-8. PubMed ID: 21498485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil - as an adjunctive immunosuppressive therapy in refractory myasthenia gravis: The Singapore experience.
    Prakash KM; Ratnagopal P; Puvanendran K; Lo YL
    J Clin Neurosci; 2007 Mar; 14(3):278-81. PubMed ID: 16597503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opportunistic infections in myasthenia gravis treated with mycophenolate mofetil.
    Termsarasab P; Katirji B
    J Neuroimmunol; 2012 Aug; 249(1-2):83-5. PubMed ID: 22613699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis.
    Langford CA; Talar-Williams C; Sneller MC
    Arthritis Rheum; 2004 Apr; 51(2):278-83. PubMed ID: 15077273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study.
    Ciafaloni E; Massey JM; Tucker-Lipscomb B; Sanders DB
    Neurology; 2001 Jan; 56(1):97-9. PubMed ID: 11148243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolate mofetil in myasthenia gravis: the unanswered question.
    Phan C; Sanders DB; Siddiqi ZA
    Expert Opin Pharmacother; 2008 Oct; 9(14):2545-51. PubMed ID: 18778192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of myasthenia gravis with mycophenolate mofetil: a case report.
    Meriggioli MN; Rowin J
    Muscle Nerve; 2000 Aug; 23(8):1287-9. PubMed ID: 10918271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
    Ortega F; Sánchez-Fructuoso A; Cruzado JM; Gómez-Alamillo JC; Alarcón A; Pallardó L; Morales JM; Oliver J; Guinea G;
    Transplantation; 2011 Aug; 92(4):426-32. PubMed ID: 21760569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients.
    Cooper M; Deering KL; Slakey DP; Harshaw Q; Arcona S; McCann EL; Rasetto FA; Florman SS
    Transplantation; 2009 Aug; 88(4):514-20. PubMed ID: 19696634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil treatment of myasthenia gravis.
    Cahoon WD; Kockler DR
    Ann Pharmacother; 2006 Feb; 40(2):295-8. PubMed ID: 16403848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.